PRESS RELEASES<< Back
Chimerix to Participate in September Investor Conferences
Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright20th Annual Global Investment Conferenceon Thursday, September 6, 2018at 8:45 a.m. ETin New York City.
A live audio webcast of Dr. Nichols’ presentation at the
- Citi 13th Annual
Biotech Conferenceon Wednesday September 5, 2018in Boston, and, Morgan Stanley Global Healthcare Conferenceon Wednesday, September 12, 2018in New York City.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
Source: Chimerix, Inc.